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SUMMARY
Growth factors have been implicated in pancreatic carcinogenesis. In this study we analyzed the
effect of Tgfa overexpression in addition to mutant KrasG12D by crossing Elastase-Tgfa mice with
p48+/Cre;Kras+/LSL-G12D mice. We show that concomitant expression of TGFa and KrasG12D acceler-
ates the progression of mPanIN lesions to metastatic pancreatic cancer and leads to the develop-
ment of cystic papillary lesions resembling human intraductal papillary mucinous neoplasms
(IPMN). Microarray data in mice revealed an IPMN signature and IPMNs expressed MUC1 and
MUC5AC but not MUC2, similar to human pancreatobiliary IPMNs. Invasive ductal adenocarcinoma
developed from PanINs and IPMNs, suggesting precursor lines for both lesion types in this model.
In conclusion, Egfr signaling in synergy with oncogenic Kras may be a prerequisite for IPMN
development and progression to pancreatic cancer.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) has an overall
5-year-survival rate below 5% without substantial
improvements within the last 20 years despite improving
surgical and medical treatment modalities (Allison et al.,
1998; Schneider et al., 2005; Warshaw and Fernandez-
del Castillo, 1992). To date, three different precursor
lesions for invasive pancreatic ductal adenocarcinoma
(PDAC) have been described: pancreatic intraepithelial
neoplasia (PanIN), intraductal papillary mucinous neo-
plasm (IPMN), and mucinous cystic neoplasm (MCN),
with PanINs being the best characterized of these lesions
(Brugge et al., 2004; Maitra et al., 2005). The identification
and classification of PanINs as precursors of PDAC
(Hruban et al., 2004) have led to the development of amor-266 Cancer Cell 12, 266–279, September 2007 ª2007 Elsevier Iphological and genetic progression model of pancreatic
cancer (overview in Hezel et al., 2006) and have facilitated
the development of sophisticated genetically engineered
mouse models for pancreatic cancer (Hruban et al.,
2006). However, of multiple approaches, only mouse
models with an endogenous KrasG12D mutation recapitu-
lated the full spectrum of human pancreatic carcinogene-
sis with murine PanIN (mPanIN) lesions progressing to
PDAC (Guerra et al., 2003; Hingorani et al., 2003). While
these mice develop metastasizing PDAC only at an
advanced age, subsequent studies using mice with
combinatorial conditional induction of KrasG12Dwith either
mutated Tp53R172H or with loss of p16/Ink4a, p19/Arf, or
Tp53 have demonstrated that additional genetic alter-
ations typically found in the human disease accelerate
the carcinogenic process (Aguirre et al., 2003; BardeesySIGNIFICANCE
Pancreatic ductal adenocarcinoma (PDAC) is thought to develop from PanIN, IPMN, and MCN preneoplastic le-
sions with PanIN lesions being the most prevalent and best-characterized precursors to pancreatic cancer. Cystic
neoplasms are increasingly diagnosed, yet their management is challenged by their heterogeneity. IPMNs are
among the most common cystic lesions; however, their molecular alterations and malignant potential are still
largely unknown. We present here an endogenous model of PDAC in which cystic papillary tumors with strong re-
semblance to human IPMNs of the pancreatobiliary type develop. Moreover, these lesions progress to invasive
cancer. In this model we provide evidence for different types of pancreatic precursor lesions developing in the
same genetic background, thus enabling identification of common and alternating genetic alterations.nc.
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Mouse Model of KrasG12D and Tgfa Activationet al., 2006a; Hingorani et al., 2005). Interestingly, each
additional genetic alteration led to different biological
tumor features demonstrating the dependence of the
phenotype and biological course of the resulting malig-
nant tumors from the respective genotype (Siveke and
Schmid, 2005). Of note, PDAC developed through PanIN
lesions and not through IPMNs or MCNs suggesting that
other factors or pathways may be important for the induc-
tion, progression, and malignant transformation of these
particular precursor lesions. IPMN and MCN belong to
a group of pancreatic cystic neoplasms that are increas-
ingly recognized as relevant clinical entities (Furukawa
et al., 2005; Kosmahl et al., 2004). While PanINs can
now be excellently studied in mouse models, IPMN and
MCN precursor lesions have been difficult to analyze
with regard to their molecular properties and malignant
potential partially due to the lack of suitable mouse
models. In a recent study in which patients with an in-
creased familial risk of developing PDAC were under
intense medical observation, IPMNs were more often
seen than advanced PanINs, suggesting that IPMN
precursor lesions are a much more common part of the
premalignant phenotypic spectrum (Canto et al., 2006).
Recently, mousemodels with concomitant conditional ac-
tivation of KrasG12D and heterozygosity or loss of Smad4
have been described in which MCN and IPMN lesions
developed, suggesting that Smad4 plays an important
and context-dependent role in cell fate, differentiation,
and precursor lesion decisions (Bardeesy et al., 2006b;
Izeradjene et al., 2007).
In addition to genetic alterations in CDKN2/INK4A,
TP53, orDPC4/SMAD4, substantial evidence from human
and murine PDAC studies implies an important role of
growth factor signaling in the carcinogenic process (Bar-
ton et al., 1991; Friess et al., 1999). In an early mouse
model studying the role of Tgfa in the pancreas, mice
with transgenic overexpression of TGFa under control of
the pancreatic Elastase promoter (Ela-Tgfa), acino-ductal
transdifferentiation, and at advanced age, development of
PDAC with similar genetic alterations as those found in
humans was demonstrated (Sandgren et al., 1990;
Wagner et al., 1998, 2001). However, these mice did not
develop PDAC through well-defined premalignant
mPanIN lesions. In an effort to study the role of Egfr signal-
ing in pancreatic carcinogenesis, we have combined two
mouse models for PDAC, Ela-Tgfa transgenic mice and
conditional p48+/Cre;Kras+/LSL-G12D mice for generating
p48+/Cre;Kras+/G12D;Ela-Tgfa mice.
RESULTS
KrasG12D;Ela-Tgfa Mice Develop Cystic Papillary
Neoplasms
To develop amodel of PDACminimizing the risk of acquir-
ing extrapancreatic oncogenic pathologies,Kras+/LSL-G12D
mice were crossed to pancreas-specific p48+/Cre mice,
which have been generated in our lab (Nakhai et al.,
2007; p48+/Cre; Kras+/LSL-G12D will be termed KrasG12D
hereafter). Ptf1a, also known as p48, is required forCanccommitment of all pancreatic lineages and specifying an
exocrine cell fate. These mice, as expected, revealed
essentially the same preneoplastic andmalignant features
as mice described by Hingorani et al. (Hingorani et al.,
2003). Induction and progression of CK19+ andMUC5AC+
mPanIN lesions tometastatic PDACoccurred as reported,
and pancreas-specific recombination was confirmed
using a Rosa26rlacZ reporter mouse (see Figure S1 in the
Supplemental Data available with this article online),
demonstrating that our p48+/Cremice function in a manner
similar to previously reported p48/Ptf1a-Cre mice (Kawa-
guchi et al., 2002). To analyze the effect of concomitant
expression of mutated KrasG12D and TGFa, we crossed
KrasG12D mice with Ela-Tgfa mice. KrasG12D;Ela-Tgfa
mice were born at expected Mendelian ratios and grew
to adulthood without visible phenotypic abnormalities
making them indistuingishable from wild-type (WT),
KrasG12D, and Ela-Tgfa littermates.
When KrasG12D;Ela-Tgfa mice were analyzed at 2 to 3
months of age, we observed a severely altered pancreas
compared to littermate genotypes with small and large
cysts and various types of ductal lesions. Acino-ductal
metaplasia, mPanIN, and cystic papillary lesions had al-
most completely replaced the acinar tissue (Figures 1A
and 1B). mPanIN lesions ranged from mPanIN-1A to 2
lesions. We also noted some mPanIN-3 lesions, which
sometimes had a cystic appearance (Figures 1C–1F).
These high-grade lesions are almost never seen in
KrasG12D pancreata at this age, suggesting an accelerated
mPanIN progression. Interestingly, in addition to acino-
ductal and mPanIN lesions, we noticed a third type of
lesion characterized by papillary cell proliferations which
had formed in branches of the main pancreatic duct (Fig-
ures 1G–1I). Mucin production by these cystic papillary
lesions was demonstrated by PAS staining (Figure 1J).
When compared with two mucin-producing cystic neo-
plasms of the human pancreas, MCN and IPMN, the
mouse cystic papillary neoplasms resembled more
closely human IPMNs than MCNs because of the lack of
ovarian-like stroma (Hruban et al., 2006).
Cystic Papillary Lesions ofKrasG12D;Ela-TgfaMice
Do Not Originate from Differentiated Acinar Cells
To prove that the cystic papillary lesions derive from
p48+ cells, we crossed Rosa26rlacZ reporter mice with
Kras+/G12D;Ela-Tgfa mice. As expected, we found these
papillary lesions to originate from p48+ cells (Figure 2A),
suggesting that they derive from either pancreatic stem,
acinar, or duct-like cells. To test whether these cystic pap-
illary lesions were also inducible in PDX1+ cells, Pdx1-Cre;
Kras+/G12D;Ela-Tgfa mice were analyzed at 3 months of
age, at which both mPanIN and cystic papillary lesions
were detected (data not shown) supporting the hypothesis
that both preneoplastic lesions may originate from a com-
mon precursor cell and not from a terminally differentiated
acinar cell.
We next addressed the hypothesis whether acinar cells
are potential precursors of IPMN-like lesions. Therefore,
we replaced p48+/Cre mice by Elastase-Cre-ER mice forer Cell 12, 266–279, September 2007 ª2007 Elsevier Inc. 267
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Mouse Model of KrasG12D and Tgfa ActivationFigure 1. Histology of Different Ductal
Lesions in KrasG12D;Ela-Tgfa Mice
(A) Gross morphology reveals replacement of
acinar tissue by cysts and various small and
large ductal structures.
(B) Acinoductal metaplasia (arrowhead),
mPanIN (arrow), and cystic papillary lesions (*)
are present.
(C–F) mPanIN1A+B (C), 2 (D),3 (E) and cystic
mPanIN3 (F) lesions.
(G–I) KrasG12D;Ela-Tgfa pancreata (G) contain
small (H, arrowhead) and large (I) cystic papil-
lary lesions with adjacent mPanINs (H, arrow).
(J) PAS stain reveals highmucin content in cells
of papillary lesions.
Mice are 9–13 weeks of age; scale bar is 50 mm
or as shown.induction of KrasG12D expression. By an additional cross-
ing, we generated Ela-Cre-ER;KrasG12D;Ela-Tgfa mice
with the Rosa26rlacZ allele for monitoring of Tamoxifen
(TM)-induced Cre recombination and cell lineage tracing.
Application of multiple TM injections 4 weeks after birth
induced widespread Cre-dependent recombination in
Ela-Cre-ER;KrasG12D;Ela-Tgfa;Rosa26rlacZ mice 4 and
15 weeks after injections as examined by positive X-gal
staining of acinar but not ductal or islet cells, whereas
only very few if any acinar cells were X-gal positive in
vehicle-treated animals (Figure 2B and data not shown).
To analyze the induction of mPanIN and/or IPMN-like
lesions, four Ela-Cre-ER;KrasG12D;Ela-Tgfa;Rosa26rlacZ
mice were followed for 15 weeks. In three of these ani-
mals, we found acino-ductal metaplasia and only rarely
mPanIN1 lesions, although mPanIN1 lesions were some-
times difficult to distinguish from acino-ductal metaplasia
(Hruban et al., 2006). Interestingly, one mouse showed
formation of very few small-sized IPMN-like lesions
(Figure 2C). To further validate the hypothesis whether
cystic papillary lesions from KrasG12D;Ela-Tgfa mice may
originate from acinar cells or acino-ductal metaplasia,
we used double-immunofluorescence for amylase and
CK19 to identify potential double-positive cystic papillary
lesions. When double-immunofluorescence for amylase268 Cancer Cell 12, 266–279, September 2007 ª2007 Elsevier Iand CK19 was applied to KrasG12D;Ela-Tgfa pancreata at
different stages of carcinogenesis, we found tubular com-
plexes with acino-ductal metaplasia staining positive for
acinar and ductal marker as expected (Figures 2D and
2E). However, we failed to observe clear double-positive
cells within IPMN-like lesions. In fact, most IPMNs like
mPanINs were CK19 single-positive, although amylase
single-positive cells were infrequently found in IPMN-like
lesions (Figure 2E and 2F). Thus, while these data do not
prove a ductal or progenitor cell as precursor of IPMN-
like lesions, we found this lesion type to be clearly distin-
guishable from acino-ductal metaplastic lesions. We next
sought to examine IPMN-like lesions with regard to path-
ways involved in specification of embryonic and adult
pancreatic cell fate. As activation of hedgehog signaling
was recently reported in human IPMNs and mPanIN
lesions (Ohuchida et al., 2006; Hingorani et al., 2003), we
investigated the expression of SHH. While we observed
SHH-positive mPanIN lesions in Kras+/G12D;Ela-Tgfa
mice, we found no definite expression in IPMN-like lesions
at 9–13 weeks of age (Figure 2G). Moreover, we found no
increased expression of the Hedgehog target genes Gli1
and Gli2 in Kras+/G12D;Ela-Tgfa pancreata compared to lit-
termate controls as determined by qRT-PCR in pancreatic
mRNA of young animals 7 days of age (data not shown),nc.
Cancer Cell
Mouse Model of KrasG12D and Tgfa Activationa time at which many genes implicated in IPMN carcino-
genesis are already detectable (see below). Thus, these
data suggest that Hedgehog signaling has no prominent
role in IPMN lesion formation in this model. Finally, we
investigated the involvement of Notch signaling in IPMN-
like lesions. Activation of this pathway can be assessed
by nuclear expression of the Notch signaling target gene
Figure 2. Immunohistochemical Analysis of Cystic Papillary
Lesions in KrasG12D;Ela-Tgfa Mice
(A) mPanIN (arrow) and cystic papillary lesions (arrowhead) are X-gal
positive in KrasG12D;Ela-Tgfa;Rosa26rlacZ reporter mice demonstrating
Cre-induced recombination in both lesion types.
(B) Acinar, but not islet and ductal cells, are X-gal positive 15 weeks
after Tamoxifen-induced Cre recombination in Ela-Cre-ER;KrasG12D;
Ela-Tgfa;Rosa26rlacZ mice.
(C) Formation of mPanIN (arrow) and cystic papillary lesions (arrow-
head) in Ela-Cre-ER;KrasG12D;Ela-Tgfa mice 15 weeks after induction.
(D) Double-immunofluorescence for amylase (green) and CK19 (red)
reveals double-positive cells within tubular complexes with acinoduc-
tal metaplasia (arrowhead).
(E) While many IPMNs (i) and PanINs (p) are CK19 single-positive,
acino-ductal metaplastic lesions (m) next to acini (a) express amylase.
(F) Amylase-positive cells can be found in IPMN-like lesions. Nuclei
were counterstained with DAPI. Mice are 18 weeks of age.
(G) Shh staining reveals expression in mPanIN (arrow), but not cystic
papillary lesions (arrowhead), of KrasG12D;Ela-Tgfa mice.
(H) HES1 expression is high in mPanIN and cyst-lining cells (arrows)
with lower expression in papillary cells of cysts (arrowhead).
Analysis of KrasG12D;Ela-Tgfa mice at 9 weeks of age or as noted.
Scale bar, 50mm.CancHES1. Importantly, centroacinar cells, which are thought
to represent pancreatic progenitor cells, are characterized
by nuclear expression of HES1 and have been implicated
as cells of origin of ductal tumors (Stanger et al., 2005).
To define the role of Notch activation and centroacinar
cells as potential source of preneoplastic lesions in
KrasG12D;Ela-Tgfa mice, we analyzed the amount and
localization of HES1 positive cells at different time points.
As described previously, we found HES1 expression to be
restricted to centroacinar cells in normal pancreata and in
mPanIN lesions of KrasG12D mice at 7 days and 3 months
of age (Figures S2A and S2B). While we did not observe
HES1 expression in Ela-Tgfa pancreata, KrasG12D;Ela-
Tgfa mice showed strong and early expression of HES1
in exocrine cells at 7 days (Figure S2C). In older mice with
distinct preneoplastic lesions,HES1expressionwas found
in cells of acino-ductal metaplastic structures, mPanIN
and cystic papillary lesions (Figure S2D). Regarding ex-
pression in cystic papillary lesions, HES1 expression was
observed in the flat cystic epithelium surrounding the pap-
illary proliferations as well as in the papillary lesions them-
selves, suggesting a role for Notch signaling activation
during IPMN lesion development (Figure 2H).
Immunohistochemical Analysis of the Cystic
Papillary Lesions Reveals Key Characteristics
of Human IPMNs of the Pancreatobiliary Type
Human IPMNs can be divided into four main types based
on morphological features and the expression of MUC1,
MUC2, MUC5AC, and CDX2 as recently described (Furu-
kawa et al., 2005). Thus, we performed immunohisto-
chemical staining for MUC1, 2, and 5AC in sections of
Kras+/G12D;Ela-Tgfa mice 3 months of age and in sections
from human patients presenting with IPMNs (Figure 3).
While IPMN-like lesions from Kras+/G12D;Ela-Tgfa mice
were MUC1- and MUC5AC-positive, there was no immu-
nohistochemical reactivity for MUC2 and CDX2 (Figure 3
and Figure S3A). This pattern corresponds to the pancrea-
tobiliary type of human IPMNs. A ductal phenotype was
demonstrated by CK19 expression (Figures 2E and 2F)
since amylase and insulin staining was negative apart
from islets trapped within the cystic lesions (Figures 2E
and 2F and Figure S3B). We next analyzed the expression
of PDX1, which revealed nuclear expression in mPanIN
lesions in cells lining the cysts and in cells of the cystic
papillary lesions demonstrating the pancreatic origin of
these cells (Figure S3C).
Cystic papillary lesions have also been observed in
other mouse models of PDAC including Ela-KrasG12D,
Mist1-KrasG12D, and Ptf1a-Cre LSL-KrasG12D Smad4lox/lox
mice (Bardeesy et al., 2006b; Grippo et al., 2003; Tuveson
et al., 2006). Interestingly, cystic papillary lesions can also
be found in Ela-Tgfa mice albeit at low frequency and at
advanced age (less than 3% of Ela-Tgfa mice older than
one year of age; J.T.S., unpublished data). To evaluate
whether these cystic lesions show similarities to IPMN-
like lesions from Kras+/G12D;Ela-Tgfa mice, sections of
cystic papillary lesions from Ela-Tgfa transgenic animals
were analyzed by immunohistochemistry. While CK19,er Cell 12, 266–279, September 2007 ª2007 Elsevier Inc. 269
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Mouse Model of KrasG12D and Tgfa ActivationFigure 3. Cystic Papillary KrasG12D;Ela-Tgfa Lesions Show Characteristics of Human Pancreatobiliary IPMNs
KrasG12D;Ela-Tgfa pancreata and different human IPMNs were stained with H&E or for MUC1, MUC2, and MUC5AC. KrasG12D;Ela-Tgfa pancreata
9–12 weeks of age show similar MUC expression patterns as human pancreatobiliary IPMNs compared to gastric, intestinal, and oncocytic IPMNs.
Scale bar, 50mm.MUC1, and MUC5AC were expressed, albeit at lower
levels than in Kras+/G12D;Ela-Tgfa lesions, no expression
of MUC2 and CDX2 was notable (Figures S3D–S3F and
data not shown).
Development of Preneoplastic Lesions
in KrasG12D;Ela-Tgfa Pancreata
To evaluate the role of KrasG12D and Tgfa for early preneo-
plastic alterations, we chose 7 days and 35 days for anal-
ysis of the carcinogenic process (7 days and 35 days). At 7
days, WT and KrasG12D pancreata were macroscopically
of similar size and appearance, while pancreata of Ela-
Tgfa and KrasG12D;Ela-Tgfa mice were significantly en-
larged (data not shown). Histologically, WT and KrasG12D
pancreata were indistinguishable revealing no preneo-
plastic lesions, while Ela-Tgfa and at higher extent
KrasG12D;Ela-Tgfa pancreata revealed duct-like structures
and acino-ductal metaplasia (Figures 4A–4C). However,
no mPanIN or cystic papillary lesions were detected in
KrasG12D;Ela-Tgfa mice at this age. As Ela-Tgfa mice de-
velop acino-ductal metaplasia, expression of acinar cell-
defining geneswas analyzed by qRT-PCR, which revealed
a strong and synergistic reduction of acinar cell defining
genes such as p48 and Elastase (Figure S4A).
We next analyzed littermate mice at 35 days after birth
at which in accordance with previous data few mPanIN-1
lesions and duct-like structures had formed in KrasG12D
and Ela-Tgfa mice, respectively. In contrast to this,
KrasG12D;Ela-Tgfa mice showed a severe loss of acinar
cells along with formation of mPanIN-1 and -2 as well as270 Cancer Cell 12, 266–279, September 2007 ª2007 Elsevier Icystic papillary lesions, suggesting that development of
preneoplastic lesions starts between 7 and 35 days after
birth (Figures S4B–S4E).
Molecular Characterization of Precursor Lesions
of KrasG12D;Ela-Tgfa Mice
To further characterize the evolving lesions of KrasG12D;
Ela-Tgfa pancreata on a molecular level, whole pancreatic
cell mRNA was prepared for genomic profiling at 7 days
when precursor lesions had not yet developed. As pan-
creata of Ela-Tgfa andKrasG12D;Ela-Tgfamice were signif-
icantly larger than wild-type and KrasG12D pancreata
showing increased proliferation as determined by Cyclin
D1 staining (Figure 4D), we expected to identify a prolifer-
ation signature in these genotypes. Indeed, whenwe com-
pared expression values of genes of a common prolifera-
tion signature (Perou et al., 1999), we clearly observed
higher expression of most genes in Ela-Tgfa and KrasG12D;
Ela-Tgfa pancreata (Figure 4E). We next tested the pres-
ence of a proliferation signature by gene set enrichment
analysis (GSEA). GSEA evaluates a query microarray data
set by using a collection of gene sets (Subramanian et al.,
2005). As expected, we found a significantly upregulated
GSEA score for proliferation in Ela-Tgfa and KrasG12D;
Ela-Tgfa pancreata demonstrating the feasibility of this
analysis for detection of pathway signatures (Figure 4F).
To test if KrasG12D;Ela-Tgfa pancreata at this age reveal
an IPMN signature, we used a set of genes that was iden-
tified in a recent study to be specifically overexpressed in
human IPMNs compared to normal pancreatic ductalnc.
Cancer Cell
Mouse Model of KrasG12D and Tgfa ActivationFigure 4. Proliferation and IPMN Signature in Early KrasG12D;Ela-Tgfa Pancreata
(A–C) Histology of KrasG12D (A), Ela-Tgfa (B), and KrasG12D;Ela-Tgfa (C) pancreata demonstrates beginning acinoductal metaplasia but no precursor
lesions in 7 day Ela-Tgfa and KrasG12D;Ela-Tgfa mice (arrowhead).
(D) Cyclin D1 is highly expressed in exocrine cells of 7 day KrasG12D;Ela-Tgfa mice. Insert shows lower expression in KrasG12D mice.
(E) Image intensity display of expression levels of genes commonly activated during proliferation.
(F) GSEA analysis of KrasG12D, Ela-Tgfa, and KrasG12D;Ela-Tgfa pancreata 7 days of age for the known set of genes upregulated during proliferation.
(G)GSEAanalysis ofKrasG12D,Ela-Tgfa, andKrasG12D;Ela-Tgfapancreata 7daysof age for the knownset of genes upregulated in human IPMN tumors.
(H) Real-time quantitative RT-PCR of genes known to be upregulated in human IPMNs in 7 day pancreata of KrasG12D;Ela-Tgfamice. Genes marked
were significantly increased compared to wild-type controls (*p < 0.05; wild-type set to 1; results are expressed as mean; error bars indicate
SEM, n = 3).
(I and J) Detection of PSCA expression in cystic papillary lesions (I) of KrasG12D;Ela-Tgfa mice but not in an early mPanIN lesion (J) of KrasG12D mice
(9 weeks of age). Scale bar, 50mm.Cancer Cell 12, 266–279, September 2007 ª2007 Elsevier Inc. 271
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Mouse Model of KrasG12D and Tgfa Activationepithelial cells (Sato et al., 2004). Using this data set,
a score defined from the IPMN defining genes was calcu-
lated for all four genotypes (WT, KrasG12D, Ela-Tgfa, and
KrasG12D;Ela-Tgfa). While no significant differences were
notable between WT, KrasG12D, and Ela-Tgfa pancreata,
there was a markedly higher score in KrasG12D;Ela-Tgfa
pancreata (Figure 4G and Figure S5), suggesting that,
indeed, concomitant activation of KrasG12D and Egfr sig-
naling may be required for IPMN development.
To verify this signature we chose a random set of 21
genes upregulated in human IPMNs for analysis in real-
time qRT-PCR. As shown in Figure 4H, 9 of 21 genes
were significantly increased in KrasG12D;Ela-Tgfa mice
compared to WT pancreata and 8 of these 9 genes were
also significantly increased compared to KrasG12D pan-
creata, suggesting a potential involvement in IPMN
pathogenesis.
As Psca expression was highly increased we next
determined its tissue expression by immunohistochemis-
try. Notably, expression of PSCA was seen predominantly
in cystic papillary lesions of KrasG12D;Ela-Tgfa pancreata,
but not in early mPanIN lesions of KrasG12D mice (Figures
4I and 4J), correlating with the gene expression results.
Activation of Egfr and Stat3 in KrasG12D;Ela-Tgfa
Pancreata
We next analyzed Ras and Egfr-dependent effector
signaling pathways in the early carcinogenic process.
Analysis at 7 days revealed increased phosphorylation of
EGFR and HER2/neu and increased Egfr and Tgfa mRNA
expression in Ela-Tgfa and KrasG12D;Ela-Tgfa pancreata
(Figures 5A and 5B). Immunohistochemical analysis re-
vealed a variable expression of EGFR in some but not all
IPMN-like lesions of KrasG12D;Ela-Tgfa mice (Figure 5C).
Although we found RAS activation in KrasG12D and at
higher levels in KrasG12D;Ela-Tgfa, but not in WT and Ela-
Tgfa pancreatic lysates by RAS activity assay (data not
shown), we observed elevated levels of the phophorylated
RAS effector ERK1/2 only in Ela-Tgfa and KrasG12D;Ela-
Tgfa, but not in KrasG12D pancreatic lysates, suggesting
that TGFa-dependent EGFR signaling is involved in
ERK1/2 activation at this early stage (Figure 5A). Correlat-
ing with the results from western blot analysis, we found
increased ERK1/2 activation by immunohistochemical
analysis (Figure 5D). Interestingly, no significant upregula-
tion of phosphorylated p38 or AKT was noted in any litter-
mates in western blot and immunohistochemical analysis,
suggesting that not all Egfr or Ras-dependent signaling
pathways are activated in KrasG12D;Ela-Tgfa mice (Fig-
ure 5A and data not shown). However, PTEN levels were
slightly increased in KrasG12D;Ela-Tgfa pancreatic lysates,
suggesting that the Akt-signaling pathway may nonethe-
less be involved in KrasG12D;Ela-Tgfa carcinogenesis
(Figure 5A). We next analyzed phosphorylation of STAT3,
a typical Egfr signaling target, which has been shown to
play a role in pancreatic carcinogenesis (Greten et al.,
2002; Miyatsuka et al., 2006). Here, we found upregulation
of STAT3 phosphorylated at Tyr705 only in KrasG12D;Ela-
Tgfa pancreatic lysates suggesting selective Stat3 path-272 Cancer Cell 12, 266–279, September 2007 ª2007 Elsevierway activation through concomitant Egfr and KrasG12D
signaling (Figure 5A). Moreover, we found upregulation
of Socs3, a downstream mediator of Stat3, in KrasG12D;
Ela-Tgfa pancreatic mRNA at 7 days supporting the
hypothesis of functional Stat3 signaling (Figure 5B). Im-
portantly, both phosphorylated STAT3 protein and Stat3
and Socs3 mRNA were highly increased in KrasG12D;
Ela-Tgfa, but not Ela-Tgfa pancreata, suggesting a syner-
gistic effect of Egfr and Kras signaling in Stat3 activa-
tion. Immunohistochemical analysis revealed a highly
increased expression of phospho-STAT3 in KrasG12D;
Ela-Tgfa pancreata at 7 days but not in control littermates
(Figures S2E–S2H). At 9 weeks of age, phospho-STAT3
was found in nuclei of preneoplastic IPMN-like cells of
KrasG12D;Ela-Tgfa (Figure 5F) as well as in some mPanIN
lesions and surrounding acinar cells of KrasG12D mice
(Figure 5E). In older KrasG12D;Ela-Tgfa mice, expression
was not confined to IPMN-like lesions but was also found
in mPanIN and malignant ductal lesions (data not shown).
As Stat3 has been shown to prevent apoptosis, we next
evaluated levels of the well-known Stat3 target gene Bcl-
xL. We found Bcl-xL protein and mRNA expression to
be selectively increased in KrasG12D;Ela-Tgfa pancreata,
while the Bcl family member Bcl-2 was equally expressed
in all littermates (Figures 5A and 5B), supporting a func-
tional role for Stat3-induced inhibition of apoptosis in
KrasG12D;Ela-Tgfa carcinogenesis. When 7 daymicroarray
data sets were evaluated using a Stat3 gene set from the
Signal Transduction Knowledge Environment (STKE), we
found a high GSEA score in the KrasG12D;Ela-Tgfa data
set but not in any littermates (data not shown).
Survival Analysis and Histological Progression
of KrasG12D;Ela-Tgfa Precursor Lesions
As described above, KrasG12D;Ela-Tgfa pancreata
revealed mPanIN precursor lesions and cystic papillary
lesions similar to human IPMNs. Thus, we wondered
whether both types of precursor lesions contribute to the
development of invasive PDAC. Since we noted mPa-
nIN-2 and occasionally mPanIN-3 lesions in animals
3 months of age, an age at which these lesions are only
rarely found in KrasG12D animals (Hingorani et al., 2005),
we expected to observe an earlier development of PDAC.
Indeed, KrasG12D;Ela-Tgfa mice had an increased inci-
dence of invasive PDAC with a median survival of approx-
imately 7 months, significantly shorter than that of
KrasG12D or Ela-Tgfa mice (Figure 6A; p < 0,003). Tumors
seen were usually large and more often had a cystic ap-
pearance than PDAC from KrasG12D mice. We observed
a predominantly glandular tumor phenotype in most of
the animals with mPanIN lesions surrounding invasive tu-
mor cells, suggesting that these tumors originated from
mPanIN lesions (Figure 6B). Disseminated metastases
were found in about 50% of PDAC, predominantly in liver,
lung, peritoneum, and lymph nodes (Figure 6C and 6D and
data not shown).
Interestingly, we also observed progression of cystic
papillary lesions in a substantial fraction of animals
(20%–30%). In these mice, large intraductal cysticInc.
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Mouse Model of KrasG12D and Tgfa ActivationFigure 5. Egfr and Stat3 Signaling Pathways Are Activated in Early KrasG12D;Ela-Tgfa Carcinogenesis
(A) Protein expression of members of the Egfr, Ras, and Bcl-2 signaling pathways in representative 7 day pancreata of wild-type, KrasG12D, Ela-Tgfa,
and KrasG12D;Ela-Tgfa mice.
(B) Expression of Egfr, Stat3, andBcl-2 signalingmembers by Affymetrix gene analysis shows increased expression inKrasG12D;Ela-Tgfa pancreata at
7 days (arbitrary units; wild-type set to 1; results are expressed as mean; error bars indicate SEM, n = 3).
(C and D) IPMN-like lesions from KrasG12D;Ela-Tgfa mice at 9 weeks of age show expression of EGFR (C) and phosphorylated ERK1/2 (D).
(E and F) Phosphorylated STAT3 is expressed in some nuclei of mPanIN lesions (arrows) and surrounding acinar cells (arrowheads) of KrasG12D mice
(E) as well as in many cells of IPMN-like lesions from KrasG12D;Ela-Tgfa mice at 6 months of age (F, arrowheads). Scale bar, 50 mm.papillary neoplasms with almost complete absence of
mPanIN lesions were present showing an IPMN-like phe-
notype. These large IPMN-like lesions exhibited nuclear
atypia and a high proliferation rate as well as evidence
for invasion (Figures 6E–6G). One animal with a tumor
composed of IPMN-like lesions revealed invasion of the
duodenum (Figures 6H and 6I). As we did not note any
mPanINs or ductal complexes in this pancreas, invasive
growth of cystic papillary cells into the duodenum seems
very likely. In another mouse we noted large IPMN-like
lesions invading the kidney and spleen (Figure 6J and
data not shown). We also observed metastatic lesions
with cystic appearance in the lung and liver suggesting
that the metastases shared the cystic papillary features
of the primaries. In conclusion, KrasG12D;Ela-Tgfa mice
develop invasive andmetastatic PDAC significantly earlier
than KrasG12D mice. These cancerous lesions are either
accompanied by mPanIN lesions or by IPMN-like lesions
suggesting that PDAC in KrasG12D;Ela-Tgfa mice origi-
nates from two types of PDAC precursor lesions.
Signaling Pathways in Different Subtypes
of Human IPMNs
Given the activation of Egfr, Stat3, and Hes1 in KrasG12D;
Ela-Tgfa preneoplastic and malignant IPMNs, we evalu-
ated expression of EGFR, HER2/neu, phospho-STAT3,
phospho-ERK, phospho-AKT, and HES1 in human IPMNCancsubtypes. For this analysis, three IPMNs of either pan-
creatobiliary, intestinal, gastric, or oncocytic subtype
were evaluated for expression by immunohistochemistry
(Figure 7A). While we noted EGFR expression only in
one pancreatobiliary and one oncocytic IPMN, HER2/
neu and phospho-ERK were not detected. Phospho-AKT
was expressed in only one pancreatobiliary but all intesti-
nal and oncocytic IPMNs, suggesting a pathogenetic role
in these subtypes. Phosphorylated STAT3 was found in all
three pancreatobiliary IPMNs, albeit at varying levels and
in one of three tumors in the other subtypes, respectively
(Figure 7B). HES1 expression was found in one pancreato-
biliary (Figure 7C) and one oncocytic IPMN but was not
detected in intestinal and gastric IPMNs. Thus, while this
analysis is preliminary, phospho-STAT3 and HES1 may
be involved in the carcinogenesis of pancreatobiliary
IPMNs.
DISCUSSION
To study the effect of increased Tgfa-induced Egfr signal-
ing in an endogenous mouse model of PDAC, we have
crossed TGFa-overexpressing mice with Kras+/LSL-G12D
mice, two well-described murine models of human
PDAC (Hingorani et al., 2003; Wagner et al., 2001; Wagner
et al., 1998). The Kras+/LSL-G12Dmodel was the first mouse
model showing induction and progression of mPanINer Cell 12, 266–279, September 2007 ª2007 Elsevier Inc. 273
Cancer Cell
Mouse Model of KrasG12D and Tgfa ActivationFigure 6. Survival Analysis and Progres-
sion of mPanIN and IPMN-like Precursor
Lesions
(A) Kaplan-Meier curves show a significantly
reduced survival time of KrasG12D;Ela-Tgfa
mice compared to wild-type (WT, p < 0.001),
KrasG12D (p < 0.001), and Ela-Tgfa (p = 0.002)
littermate controls.
(B–D) Metastatic PDAC of KrasG12D;Ela-Tgfa
mice with mPanIN lesions (arrowheads) next
to invasive cancer cells (B). Liver and lung
metastasis showing similar glandular differen-
tiation as the originating pancreatic tumor (C
and D).
(E and F) Overview of a KrasG12D;Ela-Tgfa pan-
creas showing large IPMNs and fibrosis (E).
Progression of IPMN-like lesions (F). Note tran-
sition of a normal appearing cystic papillary
lesion into a lesion with highly abnormal archi-
tectural and nuclear properties (arrowhead).
(G) High proliferation of invasive PDAC with
features of an IPMC as determined by Ki-67
immunostaining.
(H and I) Invasion of the adjacent duodenum by
IPMN-like lesions (I, arrowheads). Note that the
whole pancreas consists of papillary lesions (*).
(J) Renal metastasis resembling an IPMC in
KrasG12D;Ela-Tgfa mice.
Scale bar is 50 mm or as shown.lesions to PDAC; however, the development of metastatic
PDAC occurs rather late and additional molecular
alterations needed for malignant transformation and me-
tastasis are not well defined. In this study we show that
KrasG12D;Ela-Tgfa mice develop invasive and metastasiz-
ing PDAC significantly earlier than the single mutant
models, resulting in a significantly reduced survival of
KrasG12D;Ela-Tgfa mice. Moreover, moribund mice at the
age of 6–8 months often present with disseminated
metastasis suggesting concomitant action of mutant
KrasG12D and TGFa-induced Egfr signaling for the devel-
opment of metastatic PDAC.
PDAC originates from preneoplastic precursor lesions,
of which three morphologically distinct lesion types have
been described: PanINs, the most common and best-
characterized lesion type, and two cystic lesions, IPMN274 Cancer Cell 12, 266–279, September 2007 ª2007 Elsevier Iand MCN (Maitra et al., 2005). In KrasG12D;Ela-Tgfa
mice, we observed the parallel development and progres-
sion ofmPanIN and IPMN lesions.WhilemPanIN lesions in
our model had the samemorphological and immunohisto-
logical characteristics as mPanINs from KrasG12D mice,
evidence for a true IPMN lesion type in our model is
substantiated from several observations: (1) morphologi-
cally, IPMN-like lesions from KrasG12D;Ela-Tgfa mice are
highly similar to human IPMNs on a macroscopic and
microscopic level; (2) their ductal and Mucin-producing
phenotype is confirmed by positive PAS staining and
expression of CK19 but not amylase; (3) on a molecular
level, KrasG12D;Ela-Tgfa pancreata show a significantly
increased GSEA score when compared to a human
IPMN gene signature (Sato et al., 2004); (4) many genes
upregulated in human IPMN tumors such as Psca arenc.
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Mouse Model of KrasG12D and Tgfa ActivationFigure 7. Signaling Pathways in Different
Subtypes of Human IPMNs
(A–C) Human pancreatobiliary, intestinal, gas-
tric, and oncocytic IPMNs (n = 3 for each sub-
type) were analyzed for expression of EGFR,
HER2/neu, phospho-EKR, phospho-AKT,
phospho-STAT3, and HES1. While phospho-
AKT is found mainly in intestinal and oncocytic
IPMNs, phospho-STAT3 (B) and HES1 (C) are
expressed in nuclei of cyst lining (arrow) and
papillary (arrowhead) cells of pancreatobiliary
(B and C) and oncocytic IPMNs. Scale bar,
50 mm.selectively upregulated in our model; (5) Egfr and Egfr-
dependent effector pathways such as Stat3 are activated
in both murine and human IPMN lesions and; (6) impor-
tantly, malignant transformation of IPMNs into invasive in-
traductal papillarymucinous carcinomas (IPMC) with inva-
sion and metastasis occurred in a substantial fraction of
KrasG12D;Ela-Tgfa mice, a finding also observed in sub-
sets of human IPMNs.
In humans, four subtypes of IPMNs have been pro-
posed based on the morphological appearance and on
immunohistochemical characteristics such as the
MUC1, 2, and 5AC protein expression pattern. Based on
these criteria, a gastric, intestinal, pancreatobiliary, and
oncocytic subtype can be classified with the gastric-
type IPMN involvingmainly the branch ducts and the other
subtypes involving predominantly the main duct (Furu-
kawa et al., 2005). While the gastric-type IPMN is usually
benign, the intestinal phenotype is associated with colloid
(mucinous noncystic) carcinomas of usually better prog-
nosis whereas the pancreatobiliary type of IPMN can pro-
ceed to invasive carcinomas mimicking usual and prog-
nostic fatal PDAC (Adsay et al., 2002; Luttges et al.,
2001). Applying this classification to our murine lesions
shows a high correlation to the pancreatobiliary subtype
of human IPMNs based on the morphological appear-
ance, the MUC expression pattern, and the progression
to metastatic PDAC.
Introduction of defined genetic alterations into mouse
models of PDAC have allowed dissection of genetic path-
ways leading to cystic lesions. Mice overexpressing TGFa
with inactivation of the Ink4a/Arf locus as well as COX-2
overexpressing mice under control of the K5 promoter
developed serous cystadenoma (Bardeesy et al., 2002;
Muller-Decker et al., 2006). Mucinous cystic tumors
were recently described in mice with concomitant activa-Cancetion of KrasG12D and inactivation of Smad4. In here, devel-
opment of MCNs and IPMNs was reported in p48Cre/+;
KrasLSL-G12D/+;Dpc4flox/+ and Ptf1a-Cre LSL-KrasG12D
Smad4lox/lox mice, respectively (Bardeesy et al., 2006b;
Izeradjene et al., 2007). These highly interesting findings
demonstrate the importance of Smad4 for development
of cystic precursor lesions; however, as human IPMCs
only seldom harbor mutations in the SMAD4 gene, addi-
tional pathways may be considered for IPMN and IPMC
development. The invasive and metastatic nature of
IPMCs found in KrasG12D;Ela-Tgfa mice demonstrates
a role of Egfr signaling in IPMN initiation and progression.
Since IPMNs do not develop inKrasG12Dmice with or with-
out additional inactivation of tumor suppressors such as
Tp53, p16Ink4a, or p19Arf (Aguirre et al., 2003; Bardeesy
et al., 2006a; Hingorani et al., 2003; Hingorani et al.,
2005), we hypothesize that Tgfa-induced Egfr in synergy
with Ras signaling initiates formation of papillary lesions
while KrasG12D activation has an accelerating effect. Ac-
cordingly, we find development of IPMN-like lesions in
a small subset of old Ela-Tgfa mice as a consequence of
Egfr signaling possibly in conjunction with sporadic Kras
mutation. Our biochemical and immunohistochemical
data support a role for Egfr activation, although tissue ex-
pression in murine and human preneoplastic and malig-
nant IPMN lesions was variable, possibly because of low
expression levels, a short half-life, or rapid recycling. Fur-
ther support for a role of increased EGFR signaling in
IPMN pathogenesis comes from a report showing syn-
chronous expression of EGF and EGFR in all 11 malignant
IPMNs but only in 1 of 18 malignant MCNs and 30 of 73
PDACs (Yeh et al., 2002, 2005).
Regarding the role of Egfr and Ras effectors involved in
IPMN pathogenesis, we did not find evidence for selective
activation of ERK1/2 or AKT in IPMN lesions; however, ther Cell 12, 266–279, September 2007 ª2007 Elsevier Inc. 275
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tein and a Stat3 gene signature in KrasG12D;Ela-Tgfa
mice provide evidence for an important role of this path-
way in IPMN development. The finding of activated
Stat3 signaling with increased expression of Bcl-xL
occurring correlates well with a previously identified im-
portant role for STAT3 in human PDAC (Greten et al.,
2002). Thus, a higher apoptotic resistance of precursor
cells may be a possible mechanism for the induction of
large preneoplastic papillary lesions. Moreover, Stat3
activation was recently described to be essential for the
formation of acinoductal metaplasia, showing that Stat3
plays an important role in regulation of pancreatic cell
fate and induction of pancreatic neoplasia (Miyatsuka
et al., 2006).
As activation of Stat3 is not selective for IPMNs but is
also found in PanIN lesions, it may also explain the ac-
celerated progression of PanIN lesions compared to
KrasG12D mice. In fact, despite their different histological
appearance, pancreatobiliary IPMNs and PanINs may
share common molecular alterations. This hypothesis is
underscored by expression profiling of these lesion sub-
types revealing several upregulated genes found in Pan-
INs, IPMNs, and PDACs, suggesting a common key signa-
ture for pancreatic ductal neoplasia (Sato et al., 2004). In
humans, molecular alterations typically seen in PanINs
such as KRAS, p16INK4A, TP53, or DPC4/SMAD4 muta-
tions have also been found in IPMNs, albeit at lower fre-
quency (Biankin et al., 2002; Wada, 2002). The high
degree of similarity in genetic alterations regarding the ini-
tial mutations in the progression from early to late PanIN
development led us to hypothesize that some IPMN types
may actually present as PanIN lesions in larger ducts shar-
ing the same molecular pathogenesis and possibly the
same cell of origin. Support for this hypothesis comes
from several findings, including the observation that in
some human pancreata PanINs are found in association
with IPMNs (Biankin et al., 2004), a progression model
for IPMNs similar to the one that has been described for
progression of PanIN lesions and from the fact that PanINs
may also involve large ducts while IPMNs can arise in
smaller ducts (overview in Hruban et al., 2004). Most inter-
estingly, a recent publication on the development of pre-
neoplastic lesions in patients with a family history of
PDAC reported a high occurrence of IPMN-like lesions in
patients intensively screened for development of pancre-
atic abnormalities concluding that IPMNs may be part of
the phenotypic spectrum of familial PDAC (Canto et al.,
2006).
The histological appearance of invasive IPMC invading
the duodenum, spleen, and kidneys as well as preliminary
data showing differing expression of IPMN markers in cell
lines derived from PDAC with IPMN features compared to
PDAC cell lines from the KrasG12Dmodel (data not shown)
strongly suggests development of PDAC from IPMN-like
lesions at least in some of the KrasG12D;Ela-Tgfa animals.
The observation that some KrasG12D;Ela-Tgfa pancreata
with invasive IPMN tumors consisted almost completely
of IPMN lesions while other mice had mPanIN-dominated276 Cancer Cell 12, 266–279, September 2007 ª2007 Elsevier Ipancreata suggests that cell lineages from which preneo-
plastic lesions develop are committed early to an IPMN or
PanIN accentuated carcinogenesis. If both precursor
lesions originate from the same cell of origin is a highly
interesting yet not easily addressable question. Our find-
ings of most IPMN-like lesions lacking acinar characteris-
tics as well as the very low frequency of IPMN formation in
Ela-Cre-ER;KrasG12D;Ela-Tgfa mice argues against a ter-
minally differentiated acinar cell as cell of origin. The find-
ing of early HES1 expression at 7 days correlates well with
earlier results showing expansion of undifferentiated
HES1-expressing precursor cells as a consequence of
Egfr activation (Miyamoto et al., 2003). Thus, IPMN-like
lesions likely do not originate from Tgfa-induced acino-
ductal metaplastic cells. In addition, two findings argue
against centroacinar cells as likely candidates for the
development of IPMN lesions: the only moderately acti-
vated Akt-signaling pathway and the fact that, in contrast
to recently described conditional PTEN knockout mice
(Stanger et al., 2005), IPMN-like lesions can develop in
Ela-Cre-ER;KrasG12D;Ela-Tgfa mice, albeit at low fre-
quency. Thus, we suggest IPMNs to originate from pan-
creatic progenitor cells, which may not only be activated
cell-autonomously but also in a possible autocrine or
paracrine manner, e.g., by stimulation of a potential
stem cell niche.
The strong upregulation of nuclear HES1 in the early
pancreas of KrasG12D;Ela-Tgfa mice may be an indicator
of increased Notch activation playing an important role
in IPMN initiation and development. Interestingly, the
missing or, at the most, much lower expression of SHH
in IPMN lesions compared to mPanIN lesions in our model
may suggest divergent roles of these cell fate-regulating
pathways for precursor development. The well-described
role of Hedgehog activation in PanINs (Pasca di Magliano
et al., 2006; Prasad et al., 2005; Thayer et al., 2003) and
the strong activation of Notch signaling in Tgfa-overex-
pressing models (Miyamoto et al., 2003) implies further
studying the respective role of Notch and Hedgehog
signaling in selective precursor lesion development.
In conclusion, this study demonstrates an important
role of growth factors in pancreatic carcinogenesis. Over-
expression of TGFa not only led to an acceleration of the
PanIN-to-PDAC progression in the KrasG12D model but
also to the development of cystic papillary lesions reminis-
cent of human pancreatobiliary IPMNs. Increased expres-
sion of phosphorylated STAT3 and Bcl-xL as a result of
synergistic Egfr and KrasG12D signaling suggests an im-
portant role for this pathway in the carcinogenic process,
while cell lineage experiments support the involvement
and expansion of a progenitor cell population as possible
cell of origin for the induction of IPMN lesions. In addition,
the model presented here provides evidence for the
hypothesis that different types of precursor lesions may
occur on the same genetic background. Defining both
the common and the differing molecular properties of
each type of lesion may help to dissect these clinical
entities and may provide a platform for further subtype-
specific therapeutic approaches.nc.
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Mouse Strains
Kras+/LSL-G12D, Pdx1-Cre, and Elastase-Cre-ER mice have been
described before (Gu et al., 2002; Hingorani et al., 2003; Stanger
et al., 2005). Ptf1a+/Cre knockin mice (termed p48+/Cre mice to distin-
guish them from previously described Ptf1a-Cre knockin mice [Kawa-
guchi et al., 2002]) were generated in our lab and are described in detail
elsewhere (Nakhai et al., 2007). Ela-Tgfa-hGH mice have been de-
scribed before (Sandgren et al., 1990; Wagner et al., 2001; Wagner
et al., 1998). Mice were interbred to obtain p48+/Cre; Kras+/LSL-G12D;
Ela-Tgfa (KrasG12D;Ela-Tgfa) animals on amixed 129SV;C57BL/6 back-
ground. Wild-type, p48+/Cre;Kras+/LSL-G12D (KrasG12D) and Ela-Tgfa
littermates were used as controls. All experiments were performed ac-
cording to the guidelines of the local Animal Use andCare Committees.
Affymetrix Gene Chip Analysis and GSEA
Pancreata of four mice per genotype were dissected 7 days postna-
tally. Total RNA was prepared as described above. One to five micro-
grams of labeled RNA was hybridized to mouse expression gene chip
arrays (Affymetrix Mouse Genome 430A 2.0 Array) according to Affy-
metrix protocols. Gene chips were scanned and analyzed using
Affymetrix Microarray Suite 5.0 software (MAS 5.0).
For the IPMN signature gene set we matched the 643 transcripts
listed on http://www.pathology2.jhu.edu/pancreas/IPMN to 513
unique transcript IDs from the Mouse Genome 430A 2.0 array. For
the proliferation signature gene set (Whitfield et al., 2006), 40 out of
45 genes were matched.
GSEA software was provided by the Broad Institute of MIT and Har-
vard (http://www.broad.mit.edu/gsea/). We acknowledge the use of
the gene set enrichment analysis and GSEA software (Subramanian
et al., 2005). For both gene sets, we used the default parameters of
the GSEA software package, except for the number of permutations
(1000). Each genotype was tested against all other genotypes (WT,
KrasG12D, Ela-Tgfa, and KrasG12D;Ela-Tgfa).
Statistical Analyses
Kaplan-Meier curves were calculated using the survival time for each
mouse from all littermate groups (WT, KrasG12D, Ela-Tgfa, and KrasG12D;
Ela-Tgfa). The log-rank test was used to test for significant differences
between the four groups. For gene expression analysis the unpaired
two-tailedStudent’s t testwasused. p<0.05wasconsideredsignificant.
Histological, Molecular, and Biochemical Analyses
Detailed descriptions of procedures are provided in the Supplemental
Data.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, one supplemental table, and five supplemental figures and
can be found with this article online at http://www.cancercell.org/
cgi/content/full/12/3/266/DC1/.
ACKNOWLEDGMENTS
We thank D.A. Tuveson, D.A. Melton, and E.P. Sandgren for the gener-
ous gift of transgenic mice and D.A. Tuveson for providing Mist1-Kras
sections. We are grateful to O. Strobel and S. Thayer for supplying the
Shh image. We thank J. Mages for his help in performing gene-profiling
experiments and M. Neuhofer and C. Ko¨hler for excellent technical
assistance. This work was in part supported by grants from Deutsche
Krebshilfe (#107195; J.T.S. and R.M.S.) and the Association for Interna-
tional Cancer Research (07-0543; J.T.S.).
Received: November 25, 2006
Revised: June 4, 2007
Accepted: August 3, 2007
Published: September 10, 2007CancREFERENCES
Adsay, N.V., Merati, K., Andea, A., Sarkar, F., Hruban, R.H., Wilentz,
R.E., Goggins, M., Iocobuzio-Donahue, C., Longnecker, D.S., and
Klimstra, D.S. (2002). The dichotomy in the preinvasive neoplasia to
invasive carcinoma sequence in the pancreas: Differential expression
of MUC1 andMUC2 supports the existence of two separate pathways
of carcinogenesis. Mod. Pathol. 15, 1087–1095.
Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A.,
Horner, J., Redston, M.S., and DePinho, R.A. (2003). Activated Kras
and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic
ductal adenocarcinoma. Genes Dev. 17, 3112–3126.
Allison, D.C., Piantadosi, S., Hruban, R.H., Dooley, W.C., Fishman,
E.K., Yeo, C.J., Lillemoe, K.D., Pitt, H.A., Lin, P., and Cameron, J.L.
(1998). DNA content and other factors associated with ten-year
survival after resection of pancreatic carcinoma. J. Surg. Oncol. 67,
151–159.
Bardeesy, N., Aguirre, A.J., Chu, G.C., Cheng, K.H., Lopez, L.V., Hezel,
A.F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al.
(2006a). Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain
progression of pancreatic adenocarcinoma in the mouse. Proc. Natl.
Acad. Sci. USA 103, 5947–5952.
Bardeesy, N., Cheng, K.H., Berger, J.H., Chu, G.C., Pahler, J., Olson,
P., Hezel, A.F., Horner, J., Lauwers, G.Y., Hanahan, D., and Depinho,
R.A. (2006b). Smad4 is dispensable for normal pancreas development
yet critical in progression and tumor biology of pancreas cancer.
Genes Dev. 20, 3130–3146.
Bardeesy, N., Morgan, J., Sinha, M., Signoretti, S., Srivastava, S.,
Loda, M., Merlino, G., and DePinho, R.A. (2002). Obligate roles for
p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic
neoplasia. Mol. Cell. Biol. 22, 635–643.
Barton, C.M., Hall, P.A., Hughes, C.M., Gullick, W.J., and Lemoine,
N.R. (1991). Transforming growth factor alpha and epidermal growth
factor in human pancreatic cancer. J. Pathol. 163, 111–116.
Biankin, A.V., Biankin, S.A., Kench, J.G., Morey, A.L., Lee, C.S., Head,
D.R., Eckstein, R.P., Hugh, T.B., Henshall, S.M., and Sutherland, R.L.
(2002). Aberrant p16(INK4A) and DPC4/Smad4 expression in intraduc-
tal papillary mucinous tumours of the pancreas is associatedwith inva-
sive ductal adenocarcinoma. Gut 50, 861–868.
Biankin, A.V., Kench, J.G., Biankin, S.A., Lee, C.S., Morey, A.L., Dijk-
man, F.P., Coleman, M.J., Sutherland, R.L., and Henshall, S.M.
(2004). Pancreatic intraepithelial neoplasia in association with intra-
ductal papillary mucinous neoplasms of the pancreas: Implications
for disease progression and recurrence. Am. J. Surg. Pathol. 28,
1184–1192.
Brugge, W.R., Lauwers, G.Y., Sahani, D., Fernandez-del Castillo, C.,
and Warshaw, A.L. (2004). Cystic neoplasms of the pancreas. N.
Engl. J. Med. 351, 1218–1226.
Canto, M.I., Goggins, M., Hruban, R.H., Petersen, G.M., Giardiello,
F.M., Yeo, C., Fishman, E.K., Brune, K., Axilbund, J., Griffin, C., et al.
(2006). Screening for early pancreatic neoplasia in high-risk individ-
uals: A prospective controlled study. Clin. Gastroenterol. Hepatol. 4,
766–781; quiz 665.
Friess, H., Guo, X.Z., Nan, B.C., Kleeff, O., and Buchler, M.W. (1999).
Growth factors and cytokines in pancreatic carcinogenesis. Ann. N Y
Acad. Sci. 880, 110–121.
Furukawa, T., Kloppel, G., Volkan Adsay, N., Albores-Saavedra, J.,
Fukushima, N., Horii, A., Hruban, R.H., Kato, Y., Klimstra, D.S., Long-
necker, D.S., et al. (2005). Classification of types of intraductal papil-
lary-mucinous neoplasm of the pancreas: A consensus study.
Virchows Arch. 447, 794–799.
Greten, F.R., Weber, C.K., Greten, T.F., Schneider, G., Wagner, M.,
Adler, G., and Schmid, R.M. (2002). Stat3 and NF-kappaB activation
prevents apoptosis in pancreatic carcinogenesis. Gastroenterology
123, 2052–2063.er Cell 12, 266–279, September 2007 ª2007 Elsevier Inc. 277
Cancer Cell
Mouse Model of KrasG12D and Tgfa ActivationGrippo, P.J., Nowlin, P.S., Demeure, M.J., Longnecker, D.S., and
Sandgren, E.P. (2003). Preinvasive pancreatic neoplasia of ductal phe-
notype induced by acinar cell targeting of mutant Kras in transgenic
mice. Cancer Res. 63, 2016–2019.
Gu, G., Dubauskaite, J., and Melton, D.A. (2002). Direct evidence for
the pancreatic lineage: NGN3+ cells are islet progenitors and are dis-
tinct from duct progenitors. Development 129, 2447–2457.
Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M.,
Serrano, M., Campuzano, V., and Barbacid, M. (2003). Tumor induc-
tion by an endogenous K-ras oncogene is highly dependent on cellular
context. Cancer Cell 4, 111–120.
Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and
Depinho, R.A. (2006). Genetics and biology of pancreatic ductal ade-
nocarcinoma. Genes Dev. 20, 1218–1249.
Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C.,
Jacobetz, M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A.,
et al. (2003). Preinvasive and invasive ductal pancreatic cancer and
its early detection in the mouse. Cancer Cell 4, 437–450.
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B.,
Hruban, R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. (2005).
Trp53R172H and KrasG12D cooperate to promote chromosomal
instability and widely metastatic pancreatic ductal adenocarcinoma
in mice. Cancer Cell 7, 469–483.
Hruban, R.H., Adsay, N.V., Albores-Saavedra, J., Anver, M.R., Biankin,
A.V., Boivin, G.P., Furth, E.E., Furukawa, T., Klein, A., Klimstra, D.S.,
et al. (2006). Pathology of genetically engineered mouse models of
pancreatic exocrine cancer: Consensus report and recommendations.
Cancer Res. 66, 95–106.
Hruban, R.H., Takaori, K., Klimstra, D.S., Adsay, N.V., Albores-Saave-
dra, J., Biankin, A.V., Biankin, S.A., Compton, C., Fukushima, N., Fur-
ukawa, T., et al. (2004). An illustrated consensus on the classification of
pancreatic intraepithelial neoplasia and intraductal papillary mucinous
neoplasms. Am. J. Surg. Pathol. 28, 977–987.
Izeradjene, K., Combs, C., Best, M., Gopinathan, A., Wagner, A.,
Grady, W.M., Deng, C.X., Hruban, R.H., Adsay, N.V., Tuveson, D.A.,
and Hingorani, S.R. (2007). Kras(G12D) and Smad4/Dpc4 Haploinsuf-
ficiency Cooperate to Induce Mucinous Cystic Neoplasms and Inva-
sive Adenocarcinoma of the Pancreas. Cancer Cell 11, 229–243.
Kawaguchi, Y., Cooper, B., Gannon, M., Ray, M., MacDonald, R.J.,
and Wright, C.V. (2002). The role of the transcriptional regulator
Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet.
32, 128–134.
Kosmahl, M., Pauser, U., Peters, K., Sipos, B., Luttges, J., Kremer, B.,
and Kloppel, G. (2004). Cystic neoplasms of the pancreas and tumor-
like lesions with cystic features: A review of 418 cases and a classifica-
tion proposal. Virchows Arch. 445, 168–178.
Luttges, J., Zamboni, G., Longnecker, D., and Kloppel, G. (2001). The
immunohistochemical mucin expression pattern distinguishes differ-
ent types of intraductal papillary mucinous neoplasms of the pancreas
and determines their relationship to mucinous noncystic carcinoma
and ductal adenocarcinoma. Am. J. Surg. Pathol. 25, 942–948.
Maitra, A., Fukushima, N., Takaori, K., and Hruban, R.H. (2005). Pre-
cursors to invasive pancreatic cancer. Adv. Anat. Pathol. 12, 81–91.
Miyamoto, Y., Maitra, A., Ghosh, B., Zechner, U., Argani, P., Iacobu-
zio-Donahue, C.A., Sriuranpong, V., Iso, T., Meszoely, I.M., Wolfe,
M.S., et al. (2003). Notch mediates TGF alpha-induced changes in ep-
ithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3,
565–576.
Miyatsuka, T., Kaneto, H., Shiraiwa, T., Matsuoka, T.A., Yamamoto, K.,
Kato, K., Nakamura, Y., Akira, S., Takeda, K., Kajimoto, Y., et al. (2006).
Persistent expression of PDX-1 in the pancreas causes acinar-to-duc-
tal metaplasia through Stat3 activation. Genes Dev. 20, 1435–1440.
Muller-Decker, K., Furstenberger, G., Annan, N., Kucher, D., Pohl-
Arnold, A., Steinbauer, B., Esposito, I., Chiblak, S., Friess, H., Schir-
macher, P., and Berger, I. (2006). Preinvasive duct-derived neoplasms278 Cancer Cell 12, 266–279, September 2007 ª2007 Elsevier Iin pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice.
Gastroenterology 130, 2165–2178.
Nakhai, H., Sel, S., Favor, J., Mendoza-Torres, L., Paulsen, F.,
Duncker, G.I., and Schmid, R.M. (2007). Ptf1a is essential for the differ-
entiation of GABAergic and glycinergic amacrine cells and horizontal
cells in the mouse retina. Development 134, 1151–1160.
Ohuchida, K., Mizumoto, K., Fujita, H., Yamaguchi, H., Konomi, H.,
Nagai, E., Yamaguchi, K., Tsuneyoshi, M., and Tanaka, M. (2006).
Sonic hedgehog is an early developmental marker of intraductal
papillary mucinous neoplasms: Clinical implications of mRNA levels
in pancreatic juice. J. Pathol. 210, 42–48.
Pasca di Magliano, M., Sekine, S., Ermilov, A., Ferris, J., Dlugosz, A.A.,
and Hebrok, M. (2006). Hedgehog/Ras interactions regulate early
stages of pancreatic cancer. Genes Dev. 20, 3161–3173.
Perou, C.M., Jeffrey, S.S., van de Rijn, M., Rees, C.A., Eisen, M.B.,
Ross, D.T., Pergamenschikov, A., Williams, C.F., Zhu, S.X., Lee,
J.C., et al. (1999). Distinctive gene expression patterns in humanmam-
mary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA 96,
9212–9217.
Prasad, N.B., Biankin, A.V., Fukushima, N., Maitra, A., Dhara, S.,
Elkahloun, A.G., Hruban, R.H., Goggins, M., and Leach, S.D. (2005).
Gene expression profiles in pancreatic intraepithelial neoplasia reflect
the effects of Hedgehog signaling on pancreatic ductal epithelial cells.
Cancer Res. 65, 1619–1626.
Sandgren, E.P., Luetteke, N.C., Palmiter, R.D., Brinster, R.L., and Lee,
D.C. (1990). Overexpression of TGF alpha in transgenic mice: Induc-
tion of epithelial hyperplasia, pancreatic metaplasia, and carcinoma
of the breast. Cell 61, 1121–1135.
Sato, N., Fukushima, N., Maitra, A., Iacobuzio-Donahue, C.A., van
Heek, N.T., Cameron, J.L., Yeo, C.J., Hruban, R.H., and Goggins, M.
(2004). Gene expression profiling identifies genes associated with
invasive intraductal papillary mucinous neoplasms of the pancreas.
Am. J. Pathol. 164, 903–914.
Schneider, G., Siveke, J.T., Eckel, F., and Schmid, R.M. (2005). Pan-
creatic cancer: Basic and clinical aspects. Gastroenterology 128,
1606–1625.
Siveke, J.T., and Schmid, R.M. (2005). Chromosomal instability in
mouse metastatic pancreatic cancer–it’s Kras and Tp53 after all. Can-
cer Cell 7, 405–407.
Stanger, B.Z., Stiles, B., Lauwers, G.Y., Bardeesy, N., Mendoza, M.,
Wang, Y., Greenwood, A., Cheng, K.H., McLaughlin, M., Brown, D.,
et al. (2005). Pten constrains centroacinar cell expansion and malig-
nant transformation in the pancreas. Cancer Cell 8, 185–195.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert,
B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander,
E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: A knowl-
edge-based approach for interpreting genome-wide expression
profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550.
Thayer, S.P., di Magliano, M.P., Heiser, P.W., Nielsen, C.M., Roberts,
D.J., Lauwers, G.Y., Qi, Y.P., Gysin, S., Fernandez-del Castillo, C., Yaj-
nik, V., et al. (2003). Hedgehog is an early and late mediator of pancre-
atic cancer tumorigenesis. Nature 425, 851–856.
Tuveson, D.A., Zhu, L., Gopinathan, A., Willis, N.A., Kachatrian, L.,
Grochow, R., Pin, C.L., Mitin, N.Y., Taparowsky, E.J., Gimotty, P.A.,
et al. (2006). Mist1-KrasG12D knock-in mice develop mixed differenti-
ation metastatic exocrine pancreatic carcinoma and hepatocellular
carcinoma. Cancer Res. 66, 242–247.
Wada, K. (2002). p16 and p53 gene alterations and accumulations in
the malignant evolution of intraductal papillary-mucinous tumors of
the pancreas. J. Hepatobiliary Pancreat. Surg. 9, 76–85.
Wagner, M., Greten, F.R., Weber, C.K., Koschnick, S., Mattfeldt, T.,
Deppert, W., Kern, H., Adler, G., and Schmid, R.M. (2001). A murine
tumor progression model for pancreatic cancer recapitulating the
genetic alterations of the human disease. Genes Dev. 15, 286–293.nc.
Cancer Cell
Mouse Model of KrasG12D and Tgfa ActivationWagner, M., Luhrs, H., Kloppel, G., Adler, G., and Schmid, R.M. (1998).
Malignant transformation of duct-like cells originating from acini in
transforming growth factor transgenic mice. Gastroenterology 115,
1254–1262.
Warshaw, A.L., and Fernandez-del Castillo, C. (1992). Pancreatic car-
cinoma. N. Engl. J. Med. 326, 455–465.
Whitfield, M.L., George, L.K., Grant, G.D., and Perou, C.M. (2006).
Common markers of proliferation. Nat. Rev. Cancer 6, 99–106.
Yeh, T.S., Jan, Y.Y., Chiu, C.T., Ho, Y.B., Chen, T.C., Lee, K.F., Chan,
K.M., Hsu, J.C., Hwang, T.L., and Chen, M.F. (2002). CharacterisationCanceof oestrogen receptor, progesterone receptor, trefoil factor 1, and epi-
dermal growth factor and its receptor in pancreatic cystic neoplasms
and pancreatic ductal adenocarcinoma. Gut 51, 712–716.
Yeh, T.S., Tseng, J.H., Liu, N.J., Chen, T.C., Jan, Y.Y., and Chen, M.F.
(2005). Significance of cellular distribution of ezrin in pancreatic cystic
neoplasms and ductal adenocarcinoma. Arch. Surg. 140, 1184–1190.
Accession Numbers
Microarray data are available at ArrayExpress (http://www.ebi.ac.uk/
arrayexpress; accession number E-TABM-304).r Cell 12, 266–279, September 2007 ª2007 Elsevier Inc. 279
